AusCann lists on US stock exchange to boost international operations

AusCann lists on US stock exchange to boost international operations

One of Australia's leading listed cannabis companies has jumped across the Pacific to list on one of America's leading stock exchanges.

AusCann Group (ASX: AC8) has commenced trading on the US OTCQX Market under the stock symbol ACNNF.

The OTCQX is an investor-focused US market featuring US and global companies. To qualify for listing companies must meet high financial standards, follow best practice governance, and demonstrate compliance with US securities laws.

AusCann managing director Elaine Darby says the company listed on the OTCQX to broaden its international investor base, particularly in North America where it already has operations.

"We believe the company will benefit significantly from the increased global exposure cross-trading will provide us and we look forward to strengthening our international partnerships," says Darby.

"As regulatory changes are enacted worldwide and the benefits of cannabinoid medicines become more accepted, AusCann is seeing an increasing number of opportunities to expand its global footprint."

The company will continue to trade on the ASX.

In August, AusCann announced its consumer product is on its way to pharmacy shelves, after the company finished an important clinical trial.

With the trial completed, AusCann now hopes its first proprietary medicines will be released to the market in the first half of 2019.

The Australian group has been working closely with experts in the legal-weed capital of the US, Colorado, to develop modelling and laboratory scale proof of concept work of the new drug.

In July 2018, AusCann announced it had raised $33.4 million to fund its research and development phase. The company says this money raised will now go towards releasing the product to the market in 2019.

AusCann has also earmarked the funds for several key developments including clinical studies, expansion of manufacturing facilities, establishment of a new facility in Chile and crucial R&D into cannabinoid pharmaceuticals.

Shares in AusCann are up 7.53 per cent to $1 per share at 10.23am AEST.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Interest rates: To fix or not to fix?
Partner Content
Interest rates are on the move as evidenced by another rise issued by the Reserve Bank ...
WMS
Advertisement

Related Stories

Adore Beauty CEO Tennealle O’Shannessy tenders resignation

Adore Beauty CEO Tennealle O’Shannessy tenders resignation

Online cosmetics retailer Adore Beauty (ASX: ABY) CEO Tennealle O&r...

Mirvac fattens margins, loads up on emerging opportunities as profit hits $906m

Mirvac fattens margins, loads up on emerging opportunities as profit hits $906m

Mirvac Group (ASX: MGR) is beating the odds in the troubled residen...

Adelaide’s controversial $95m ORTA development gets green light to proceed

Adelaide’s controversial $95m ORTA development gets green light to proceed

A consortium of local developers has been given the green light to ...

GIC acquires half-stake in Charter Hall’s $1.5 billion 555 Collins Street tower

GIC acquires half-stake in Charter Hall’s $1.5 billion 555 Collins Street tower

Leading property investment management company Charter Hall has sol...